A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
James R. Berenson(Oncotherapeutics (United States)), Robert Vescio(Royal Adelaide Hospital), Kenneth Dressler(St. Vincent's Medical Center), Edwin Kingsley(Comprehensive Cancer Centers of Nevada), James Hilger, Stephen J. Noga, Ori Yellin, Youram Nassir, Saad Jamshed(Unity Health System), Jeffrey Matous(Colorado Blood Cancer Institute), Wael A. Harb, Hassan Ghazal(Mohamed I University), Ralph V. Boccia(Center for Cancer and Blood Disorders), Regina A. Swift(Institute for Myeloma & Bone Cancer Research)
Cited by 36
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425